Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.

Breast cancer research : BCR - 1 Jan 2008

Eerola Hannaleena, Heinonen Mira, Heikkilä Päivi, Kilpivaara Outi, Tamminen Anitta, Aittomäki Kristiina, Blomqvist Carl, Ristimäki Ari, Nevanlinna Heli

Abstract excerpt

INTRODUCTION: Finding new immunohistochemical markers that are specific to hereditary breast cancer could help us to select candidates for BRCA1/BRCA2 mutation testing and to understand the biological pathways of tumour development. METHODS: Using breast cancer tumour microarrays, immunohistochemical expression of cytokeratin (CK)-5/6, CK-14 and CK-17 was evaluated in breast tumours from BRCA1 families (n = 46),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis Regulatory Proteins
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Immunohistochemistry

Share to Keratin-14

Share to Keratin-5

Share to Keratin-6

Share to Keratins

Source

Open in PubMed Open full text

Identifiers

PMID: 18275599
DOI: 10.1186/bcr1863
PMCID: PMC2374973

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.PMID 18275599Read ↗

Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors.Semantic proximity Read ↗

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.Semantic proximity Read ↗

CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry.Semantic proximity Read ↗

Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype.Semantic proximity Read ↗

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.Semantic proximity Read ↗

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.Semantic proximity Read ↗

Prognostic relevance of basal cytokeratin expression in operable breast cancer.Semantic proximity Read ↗

Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers.Semantic proximity Read ↗

Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.Semantic proximity Read ↗

Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier predictionSemantic proximity Read ↗

Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.Semantic proximity Read ↗

Expression of luminal and basal cytokeratins in human breast carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.